血浆一氧化氮在酒精性心肌病疗效评估中的作用  

The Role of Plasma Nitric Oxide Level in Response Evaluation of the Patients with Alcoholic Cardiomyopathy

作　　者：马双陶[1] 杨大春[1] 陈劲松[1] 唐兵[1] 李德[1] 杨永健[1] 

机构地区：[1]成都军区总医院心血管内科,四川成都610083

出　　处：《现代生物医学进展》2011年第16期3114-3116,共3页Progress in Modern Biomedicine

基　　金：成都军区医学科研"十一五"课题(MB09023)

摘　　要：目的:探讨血浆一氧化氮(NO)水平在酒精性心肌病(ACM)患者疗效评估中的作用。方法:纳入32例ACM患者,给予戒酒和心力衰竭的标准治疗,治疗前和治疗3个月后行超声心动图检查评估左室舒张末期内径(LVEDD)和左室射血分数(LVEF),检测血浆NO水平。比较治疗前后NO的水平,并将NO水平的变化幅度与治疗后LVEDD和LVEF的变化幅度进行相关性分析。结果:治疗3个月后血浆NO的水平显著高于治疗前的水平(22.86±6.61μmol/L vs.26.23±6.52μmol/L,P<0.01)。治疗3个月后血浆NO水平的增加幅度与LVEDD的降低幅度(r=0.78,95%CI:0.60～0.89,P<0.01)和LVEF的升高幅度(r=0.75,95%CI:0.55～0.87,P<0.01)均显著相关。结论:血浆NO水平的变化可用于评估ACM患者的疗效。Objective： To investigate the effect of plasma nitric oxide （NO） in patients with alcoholic cardiomyopathy （ACM）. Methods： 32 patients with ACM were chosen. Left ventricular end diastolic diameter （LVEDD）, left ventricular ejection fraction （LVEF） and plasma NO levels were detected. Results： After three-month intervention, the plasma NO level was significantly higher than that at baseline （22.86±6.61μmol/L vs. 26.23± 6.52μmol/L, P〈0.01）. And the increasing of the plasma NO was significantly correlated with both the decreasing of LVEDD （r=0.78,95%CI： 0.60 -0.89, P〈0.01） and the increasing of LVEF （r=0.75,95%CI： 0.55 -0.87, P〈0.01）. Conclusion： The change of plasma NO might be used in the evaluation of ACM.

关 键 词：酒精性心肌病 一氧化氮 疗效 

分 类 号：R542.2[医药卫生—心血管疾病]